These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 7981178

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Isolation and partial characterization of lipoprotein A-II (LP-A-II) particles of human plasma.
    Bekaert ED, Alaupovic P, Knight-Gibson C, Norum RA, Laux MJ, Ayrault-Jarrier M.
    Biochim Biophys Acta; 1992 Jun 05; 1126(1):105-13. PubMed ID: 1606170
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The effect of aggressive and moderate lowering of LDL-cholesterol and low dose anticoagulation on plasma lipids, apolipoproteins and lipoprotein families in post coronary artery bypass graft trial.
    Alaupovic P, Fesmire JD, Hunnighake D, Domanski M, Forman S, Knatterud GL, Forrester J, Herd JA, Hoogwerf B, Campeau L, Gobel FL.
    Atherosclerosis; 1999 Oct 05; 146(2):369-79. PubMed ID: 10532693
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The Monitored Atherosclerosis Regression Study (MARS). Design, methods and baseline results.
    Cashin-Hemphill L, Kramsch DM, Azen SP, DeMets D, DeBoer LW, Hwang I, Vailas L, Hirsch LJ, Mack WJ, DeBoer L.
    Online J Curr Clin Trials; 1992 Oct 23; Doc No 26():[9897 words; 83 paragraphs]. PubMed ID: 1343613
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Combining beta-adrenergic and peroxisome proliferator-activated receptor gamma stimulation improves lipoprotein composition in healthy moderately obese subjects.
    Hughes TA, Stentz F, Gettys T, Smith SR.
    Metabolism; 2006 Jan 23; 55(1):26-34. PubMed ID: 16324916
    [Abstract] [Full Text] [Related]

  • 10. Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin.
    Hodis HN, Mack WJ, Azen SP, Alaupovic P, Pogoda JM, LaBree L, Hemphill LC, Kramsch DM, Blankenhorn DH.
    Circulation; 1994 Jul 23; 90(1):42-9. PubMed ID: 8026027
    [Abstract] [Full Text] [Related]

  • 11. In vitro transformation of apoA-I-containing lipoprotein subpopulations: role of lecithin:cholesterol acyltransferase and apoB-containing lipoproteins.
    Cheung MC, Wolf AC.
    J Lipid Res; 1989 Apr 23; 30(4):499-509. PubMed ID: 2502592
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Interrelationships between human apolipoprotein A-I and apolipoproteins B-48 and B-100 kinetics using stable isotopes.
    Welty FK, Lichtenstein AH, Barrett PH, Dolnikowski GG, Schaefer EJ.
    Arterioscler Thromb Vasc Biol; 2004 Sep 23; 24(9):1703-7. PubMed ID: 15242863
    [Abstract] [Full Text] [Related]

  • 15. Dietary hydrogenated fat increases high-density lipoprotein apoA-I catabolism and decreases low-density lipoprotein apoB-100 catabolism in hypercholesterolemic women.
    Matthan NR, Welty FK, Barrett PH, Harausz C, Dolnikowski GG, Parks JS, Eckel RH, Schaefer EJ, Lichtenstein AH.
    Arterioscler Thromb Vasc Biol; 2004 Jun 23; 24(6):1092-7. PubMed ID: 15087307
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effect of fluvastatin on intermediate density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia.
    Broyles FE, Walden CE, Hunninghake DB, Hill-Williams D, Knopp RH.
    Am J Cardiol; 1995 Jul 13; 76(2):129A-135A. PubMed ID: 7604788
    [Abstract] [Full Text] [Related]

  • 18. The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk.
    Walldius G, Jungner I, Aastveit AH, Holme I, Furberg CD, Sniderman AD.
    Clin Chem Lab Med; 2004 Jul 13; 42(12):1355-63. PubMed ID: 15576296
    [Abstract] [Full Text] [Related]

  • 19. Effects of simvastatin on plasma lipids and apolipoproteins in familial hypercholesterolemic swine.
    Hasler-Rapacz J, Kempen HJ, Princen HM, Kudchodkar BJ, Lacko A, Rapacz J.
    Arterioscler Thromb Vasc Biol; 1996 Jan 13; 16(1):137-43. PubMed ID: 8548414
    [Abstract] [Full Text] [Related]

  • 20. Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity.
    Ooi EM, Watts GF, Sprecher DL, Chan DC, Barrett PH.
    J Clin Endocrinol Metab; 2011 Oct 13; 96(10):E1568-76. PubMed ID: 21816786
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.